EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. More Details
Flawless balance sheet with questionable track record.
Share Price & News
How has EKF Diagnostics Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EKF is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: EKF's weekly volatility (7%) has been stable over the past year.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: EKF exceeded the UK Medical Equipment industry which returned -12.1% over the past year.
Return vs Market: EKF exceeded the UK Market which returned 1.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is EKF Diagnostics Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StEKF Diagnostics Holdings (LON:EKF) Has Rewarded Shareholders With An Exceptional 804% Total Return On Their Investment
1 month ago | Simply Wall StAt UK£0.72, Is EKF Diagnostics Holdings plc (LON:EKF) Worth Looking At Closely?
1 month ago | Simply Wall StWhat Do The Returns On Capital At EKF Diagnostics Holdings (LON:EKF) Tell Us?
Is EKF Diagnostics Holdings undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EKF (£0.68) is trading above our estimate of fair value (£0.57)
Significantly Below Fair Value: EKF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EKF is good value based on its PE Ratio (48.5x) compared to the GB Medical Equipment industry average (49.3x).
PE vs Market: EKF is poor value based on its PE Ratio (48.5x) compared to the UK market (23.8x).
Price to Earnings Growth Ratio
PEG Ratio: EKF's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: EKF's PB Ratio (3.9x) is in line with the GB Medical Equipment industry average.
How is EKF Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EKF's earnings are forecast to decline over the next 3 years (-23.3% per year).
Earnings vs Market: EKF's earnings are forecast to decline over the next 3 years (-23.3% per year).
High Growth Earnings: EKF's earnings are forecast to decline over the next 3 years.
Revenue vs Market: EKF's revenue is expected to decline over the next 3 years (-7.8% per year).
High Growth Revenue: EKF's revenue is forecast to decline over the next 3 years (-7.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EKF's Return on Equity is forecast to be high in 3 years time
How has EKF Diagnostics Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EKF has high quality earnings.
Growing Profit Margin: EKF's current net profit margins (12.8%) are lower than last year (24.6%).
Past Earnings Growth Analysis
Earnings Trend: EKF has become profitable over the past 5 years, growing earnings by 60.8% per year.
Accelerating Growth: EKF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: EKF had negative earnings growth (-40.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (-29.1%).
Return on Equity
High ROE: EKF's Return on Equity (8.4%) is considered low.
How is EKF Diagnostics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: EKF's short term assets (£35.6M) exceed its short term liabilities (£20.4M).
Long Term Liabilities: EKF's short term assets (£35.6M) exceed its long term liabilities (£4.1M).
Debt to Equity History and Analysis
Debt Level: EKF's debt to equity ratio (0.8%) is considered satisfactory.
Reducing Debt: EKF's debt to equity ratio has reduced from 7.5% to 0.8% over the past 5 years.
Debt Coverage: EKF's debt is well covered by operating cash flow (1243.4%).
Interest Coverage: EKF's interest payments on its debt are well covered by EBIT (433.9x coverage).
What is EKF Diagnostics Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EKF's dividend (1.47%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.48%).
High Dividend: EKF's dividend (1.47%) is low compared to the top 25% of dividend payers in the UK market (4.58%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether EKF's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if EKF's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (71.4%), EKF's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: EKF's dividends in 3 years are forecast to be covered by earnings (55.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Julian Baines (55 yo)
Mr. Julian Huw Baines, MBE, serves as a Director of Quotient Diagnostics Limited. Mr. Baines served as a Non-Executive Chairman of Renalytix AI plc since March 15, 2018 until July 16, 2020. Since 2009, he ...
CEO Compensation Analysis
Compensation vs Market: Julian's total compensation ($USD2.28M) is above average for companies of similar size in the UK market ($USD781.23K).
Compensation vs Earnings: Julian's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|CEO & Executive Director||no data||UK£1.64m||0.41% |
|COO, Finance Director & Executive Director||no data||UK£1.60m||0.039% |
|Non-Executive Chairman||4.83yrs||UK£50.00k||no data|
|Independent Non-Executive Director||4.58yrs||UK£50.00k||no data|
|Senior Independent Director||no data||UK£50.00k||0.37% |
Experienced Board: EKF's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
EKF Diagnostics Holdings plc's company bio, employee growth, exchange listings and data sources
- Name: EKF Diagnostics Holdings plc
- Ticker: EKF
- Exchange: AIM
- Founded: 1990
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£304.845m
- Shares outstanding: 454.99m
- Website: https://www.ekfdiagnostics.com
Number of Employees
- EKF Diagnostics Holdings plc
- Avon House
- 19 Stanwell Road
- South Glamorgan
- CF64 2EZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EKF||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Jun 2002|
|EKDH.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 2002|
EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. It offers ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/01 20:13|
|End of Day Share Price||2021/03/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.